Alpha-1-Antitrypsin-Deficiency in COVID-19

Completed

• Conditions: Covid19

• Registration Number: NCT04799873
• Lead Sponsor: Universität des Saarlandes

Brief Summary

The blood concentrations of alpha-1-antitrypsin are monitored during COVID-19. The clinical course of patients that received AAT infusion for clinical indication is monitored.

Detailed Description

The blood concentrations of alpha-1-antitrypsin are monitored during COVID-19. The clinical course of patients that received AAT infusion for clinical indication is monitored. Clinical outcomes, blood inflammatory markers, and virus load are monitored.

Study Timeline

• Study Start: 2020-04-08
• Primary Completion: 2020-12-01
• Study Completion: 2020-12-01
• Status Verified: 2021-03
• Study First Submitted: 2021-03-14
• Study First Submitted QC: 2021-03-15
• Last Update Submitted: 2021-03-15
• Study First Posted: 2021-03-16
• Last Update Posted: 2021-03-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Infection with SARS-COV2
• Age over 18 years

Read More

Exclusion Criteria

• Unability to consent
• Invasive ventilation

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical course	3 months	Disease course such as death, need for ICU treatment, ventilatory support or deterioration are monitored

Trial Locations

Locations (1)

Saarland University; 🇩🇪 Homburg, Saarland, Germany